Page last updated: 2024-09-04

vatalanib and Mesothelioma

vatalanib has been researched along with Mesothelioma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dudek, A; Green, M; Gu, L; Jahan, T; Kindler, HL; Kratzke, R; Otterson, GA; Vokes, EE; Wang, X	1
Kindler, HL	1

Reviews

1 review(s) available for vatalanib and Mesothelioma

Article	Year
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 45 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Mesothelioma; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Vascular Endothelial Growth Factor A	2004

Trials

1 trial(s) available for vatalanib and Mesothelioma

Article	Year
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung cancer (Amsterdam, Netherlands), 2012, Volume: 76, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; GPI-Linked Proteins; Humans; Male; Mesothelin; Mesothelioma; Middle Aged; Phthalazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A	2012

Article

Year

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Lung cancer (Amsterdam, Netherlands), 2012, Volume: 76, Issue:3

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; GPI-Linked Proteins; Humans; Male; Mesothelin; Mesothelioma; Middle Aged; Phthalazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A

2012